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Abstract
Rotaviruses (RV) are a common cause of severe diarrhea in young children, resulting in nearly one million deaths worldwide annually.
Rotavirus VP7 was the rotavirus neutralizing protein. Previous study reported that VP7 DNA vaccine can induce high levels of IgG in mice
but cannot protect mice against challenge (Choi, A.H., Basu, M., Rae, M.N., McNeal, M.M., Ward, R.L., 1998. Virology 250, 230–240).
We found that rotavirus VP7 could maintain its neutralizing immunity when it was transformed into the potato genome. Mice immunized
with the transformed tubers successfully elicited serum IgG and mucosal IgA specific for VP7. The mucosal IgA titer was as high as 1000,
while serum IgG titer was only 600. Neutralizing assays indicated that IgA could neutralize rotavirus. These results indicate the potential
usefulness of plants for production and delivery of edible rotavirus vaccines.
© 2003 Elsevier Science (USA). All rights reserved.
Introduction
Human rotaviruses (HRV) are the common cause of
severe diarrhea in young children and are estimated to cause
nearly one million deaths worldwide annually (Avendano et
al., 1993). RV are responsible for 6% of deaths among
children under 5 years of age and for 25% of deaths due to
diarrheal disease in developing countries. In developed
countries, where HRV-acute gastroenteritis is usually mild
(Glass et al., 1996), they still cause enormous socioeco-
nomic costs (Berner et al., 1999; Johansen et al., 1999).
Thus there is an urgent need to develop a rotavirus vaccine.
Several rotavirus vaccine candidates have been evaluated in
clinical trials with various degrees of success. The licensure
of the first rotavirus vaccine, a tetravalent rhesus-based
rotavirus vaccine, in the United States in 1998, marked a
significant advance in preventing the morbidity associated
with rotavirus diarrhea. However it was withdrawn in less
than 1 year after being associated with intussusception, a
rare form of bowel blockage found most frequently in
young children (Coste et al., 2000). These data suggested
that safety should be considered above all while developing
an RV vaccine. In recent years, experiments demonstrated
that a different vector-expressing HRV glycoprotein VP7
was capable of stimulating protective immunity and plays a
key role in protection (Andrew et al., 1992; Hoshino et al.,
1985; Wang et al., 1999). Previous studies in naturally
infected children have shown that intestinal antibodies, es-
pecially IgA, are pivotal in protection from rotavirus rein-
fection (Giammarioli et al., 1996). Oral immunization is an
efficient method of inducing high levels of mucosal IgA
injection or mainline (Choi et al., 1998) and thus an RV
vaccine may focus on an edible vaccine.
The utilization of plants as bioreactors for the production
of foreign proteins have been increasingly used to acquire
experimental immunogens. They are potentially an inexpen-
sive source of antigens that could be parenterally adminis-
tered or to be used as edible vaccines. To date, several viral
antigens have been produced in transgenic plants, which
possessed immunogenicity in animals (Haq et al., 1995;
Mason et al., 1992; Tacket et al., 1998). As yet, there are no
national data about human rotavirus antigen gene expressed
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in transgenic plants, although there are reports of murine
(epitope of NSP4) or bovine (VP6) rotavirus (Matsumura et
al., 2002; Yu and Langridge, 2001). So, using the VP7 as
the antigen in developing edible transgenic plants RV vac-
cine is a reasonable, worthwhile work and may represent a
strategy for the development of safe, effective vaccines
against rotavirus-induced diarrhea. We report here the hu-
man rotavirus group A antigen gene VP7 expressed in
transgenic potato and its immunogenicity in mice.
Results
Production and genetic analysis of transformed plants
The whole length of human group A rotavirus serotype
G1 VP7 gene with endoplasmic reticulum sequence
SEKDEL was cloned into the plant expression vector
PB1121 (Fig. 1A). We transformed the whole length of
human group A rotavirus VP7 gene into potato genome.
Twenty different transgenic plants with the ability of grow-
ing in the presence of kanamycin were produced. The pres-
ence of the VP7 gene was detected by Southern blot. A
single band of the target gene was detected in all the VP7
transformants but no band was detected in the mock-trans-
formants (Fig. 1B). The expression of the VP7 mRNA in the
transgenic plants was detected by RT-PCR. A band of 1062
bp, which was amplified with specific primers for VP7 gene,
was obtained in all the kanamycin-resistant plants tested,
while it was consistently absent in mock-transformed plants
(Fig. 1C).
Fig. 2. Detection of VP7 protein in potato plant leaf extracts by ELISAs.
Lane M: extracts of mock-transformed potatoes; lanes 1 to 20 (from left to
right): extracts of VP7-transformed potatoes numbered from 1 to 20.
Fig. 1. (A) Plant transformation vector construction for expression of rotavirus VP7 protein in potato. The T-DNA region inserted into the plant genome
contained the nopaline synthase expression cassette (KanR), which confers kanamycin resistance on transformed cells, and the human rotavirus VP7
(HRV-VP7) expression cassette. A cauliflower mosaic virus 35S promoter (35S-Pro) was used to drive the foreign gene expression and an endoplasmic
reticulum sequence SEKDEL was fused to the end of VP7 gene. (B) Detection of the VP7 by Southern blot of plant genomic DNA. Lane 1: 100 ng DNA
from PBI-VP7 recombinant plasmids; lanes 2–9: DNA from PBI-VP7-derived transformed plants; lane 10: DNA from mock-transformed potatoes. (C)
Detection of the VP7 mRNA by RT-PCR of plants total RNA. Lane 1: total RNA from wild-type potato; lanes 2–13: total RNA from PBI-VP7-derived
transformed plants; lane 14: low-range DNA markers (Sangon, China): (D) Western blot analysis of VP7 protein in the transformed potato tuber extracts
proteins. Lane 1: recombinant VP7 protein; lanes 2–5 (from left to right): VP7 transgenic plants nos. 11, 4, 8, 19; lane 6: mock-transgenic plant.
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VP7 protein expressed in the transformed plants leaves
The VP7 protein in 20 different transformed plants were
detected by ELISA. Each ELISA plate included positive
controls containing 1 to 50 ng of recombinant VP7 protein.
The amount of protein in each of the extracts was deter-
mined by the Bio-Rad protein assay. The protein levels of
VP7, ranging from 0.18 to 3.84 g/mg of soluble protein,
were observed in most transformants (Fig. 2). The maxi-
mum level of VP7 protein in the leaves reached up to 3.84
g/mg of total soluble protein. Four transgenic plants (plant
nos. 4, 8, 11, 19) with higher VP7 protein were selected for
later Western blot analysis.
VP7 protein expressed in transformants tubers
Transformed potato tuber extract proteins were analyzed
by Western blot. The molecular weight of the VP7 protein
expressed by the transgenic potato plants corresponded to
that of native VP7, which has an apparent molecular mass of
38 kDa. The reaction of the recombinant polypeptides found
in the transformants to specific antibodies also supported the
hypothesis that in those constructs the translation started at
the authentic initiation codon described for the VP7 found
in the virions (Fig. 1D). This also indicated that recombi-
nant VP7 did not undergo major posttranslational process-
ing in the plant system as other researchers reported.
Antibody titers in animal responded to the
plant-expressed VP7
Anti-VP7 titers in the sera of the animals fed with mock-
transformed potato tubers were not detectable 67 days after
immunization (Fig. 3A). By contrast, at this time the mice
immunized with VP7-derived potato tubers showed high
antibody titers (Fig. 3A), which did not increase after the
last boost. Intestinal VP7-specific and total IgA levels in the
mice of Fig. 3B were assayed by ELISA. At the same time,
the feces, the urine, and the saliva were also collected. All
of the samples were stored at 20°C until enzyme-linked
immunosorbent assay (ELISA) detection. Before analysis,
feces pellets were dissolved in PBS with 2 g ml1 sodium
azide and serially diluted with PBS. Urine and saliva were
also serially diluted with PBS and detected by ELISA. Of
the mice that had a positive serum antibody response at a
titer of 600, 18/19 (with CT) and 19/20 (with CT-B) also
had high VP7-specific intestinal IgA (Fig. 3B). However,
urine or saliva IgA titers were significantly lower (P 
0.005) than feces’ IgA titers. Specific IgA titers ranged from
150 to 1000 for CT and from 157 to 995 for CT-B. No
Fig. 3. Measurement of anti-VP7 antibody titers responses in mice after oral immunization with transgenic potato tubers. (A) Kinetics of serum IgG antibody
titers against HRV-VP7 at different times (from left to right); 1–7 represent mice blood collected on 0, 7, 14, 21, 35, 42, and 67 days. (B) Kinetics of feces
IgA antibody titers against HRV-VP7 at different times (from left to right); columns from left to right represent mice blood collected on 0, 7, 14, 21, 35,
42, and 67 days. (C) Mucosal IgA antibody titers against HRV-VP7. Columns 1–4 represent group 1, 2, 3, and 4, respectively. Columns 5–8 had the same
representation. Antibody titers were determined by immunoperoxidase ELISA method. The antibody titer was determined as the reciprocal of the highest
dilution of the samples that generated a color signal above the background levels. Group 1:2 g transformed potato tubers (containing 84 g VP7)  10 g
CT; group 2: 1 g transformed potato tubers  10 g CT; group 3: 2 g transformed potato tubers  10 g CT-B; group 4: 1 g transformed potato tubers 
10 g CT-B; group C: control group mice fed with mock-transformed potato tubers.
339Y.Z. Wu et al. / Virology 313 (2003) 337–342
VP7-specific IgA was detected in the mucosal of mice fed
with mock transformants.
Neutralize assay
To examine the functional activity of the antirotavirus
antibodies detected after oral administration of plant-de-
rived VP7 protein, in vitro rotavirus neutralization assays
were performed using sera or feces collected from day 42
(Figs. 3A and B). Sera derived from mice included with
control transgenic plants and VP7 transgenic plants showed
no neutralization activity against rotavirus Wa (Fig. 4).
Significant levels of neutralizing antibodies were, however,
detected in feces collected from mice fed with transgenic
plants (Fig. 4). While feces collected from the control group
did not detect neutralizing activity against to rotavirus Wa,
these results confirmed that transgenic plants could induce
functionally active antirotavirus intestinal antibodies.
Comparing the effect of CT with CT-B as mucosal
adjuvant
Mice orally immunized with four doses of transgenic
potato tubers with adjuvant cholera toxin (CT) or cholera
toxin subunit B (CT-B) both elicited VP7-specific IgG in
sera and IgA in mucosal system when examined on day 42.
There was no significant difference (P  0.05) of VP7-
specific IgG or IgA between immunization groups with CT
or CT-B as mucosal adjuvant.
Discussion
The mucosal immune system and its predominant effector,
secretory immunoglobulin A (IgA), provide the initial immu-
nologic barriers against most pathogens that invade the body at
a mucosal surface (Johansen and Svensson, 1997). This is
especially true for viruses, since resistance to infection has
strongly correlated with the presence of specific IgA antibody
in mucosal secretions. The characteristics and functions of
mucosal IgA appear ideally designed to maintain the integrity
of the mucosal epithelium while defending the body against
foreign pathogens and antigens (Herrmann et al., 1999). Thus
selecting a suitable antigen to immunize high IgA response is
considerable in designing a mucosal system pathogen such as
rotavirus. There of the rotavirus structure proteins VP4, VP7,
and VP6 that were used in rotavirus vaccine strategies could
independently induce neutralization antibodies (Choi et al.,
1998). Antibodies to VP4 and VP7 can passively protect mice
against rotavirus challenge (Both et al., 1993). Vaccine strat-
egies based on VP6 were also tested. An interesting note was
that IgA were always lower than IgG in the animal immuni-
zation test in previous reports, whereas our results first showed
higher IgA in mice intestinal feces immunized with VP7-
transformed potatoes and the neutralizing activity against ro-
tavirus existed in mucosal antibodies, IgA, but not in humoral
antibodies, the sera. These data demonstrated the main role of
VP7 in protecting body from rotavirus reinfection was to
stimulate the mucosal system of the body to secrete IgA. Our
results proved that VP7 gene was expressed accurately in the
plant to maintain its glycopein immunity and also indicated
that plant was a suitable express system for producing a foreign
gene such as viral immunogen.
Both CT and Escherichia coli heat-labile enterotoxin
(LT) were capable of providing adjuvant activity to an-
tigens that are coadministered orally in many cases (Rask
et al., 2000). Although CT and the closely related LT can
act as powerful mucosal adjuvants, their use in humans is
hampered by their high toxicity. Both CT and LT consist
of a homopentamer of cell-binding B subunits associated
with a single toxic active A subunit. The B subunits of
CT (CTB) and LT (LTB) can be used both as carrier
molecules and as mucosal adjuvants (Sun et al., 2000),
the efficacy of which in the latter case depends on the
route of mucosal administration. Our data in this article
showed that the immune responses and levels of neutral-
izing rotavirus were enhanced equally with CTB or CT as
a mucosal adjuvant. These would be worthwhile for fur-
ther study of construction of multivalent transgenic
plants vaccine.
In conclusion, we demonstrated here that rotavirus antigen
VP7 was successfully transformed into potato, and in animal
tests, VP7 maintained its immunogen. The neutralizing activity
against rotavirus of VP7 mainly depended on antibodies IgA
but not IgG. Plant is a candidate express system for researching
rotavirus vaccine and CTB has an equally mucosal adjuvant
effect compared to CT.
Materials and methods
Cloning VP7 gene and construction of the recombinant
plasmid
For the construction of plant expression vector PBI-VP7,
the whole VP7 gene was cloned as the following. The total
RNA was isolated from a Chinese child’s feces and used as
Fig. 4. Rotavirus neutralizing antibody titers in sera or in feces of mice oral
administered transgenic potatoes or mock transforms on 42 day after first
immunization. Column C represents control group immunized mock-trans-
genic potatoes; columns 1–4 represent groups 1, 2, 3, and 4, respectively.
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the RT-PCR template to amplify the full-length VP7 gene;
the primers were as follows: P1 5-GGCTTTAAAA-
GAGAGAATTTCCGTCTGG-3 (forward) and P2 5-GT-
CACATCATACAATTCTAATCTAAG-3 (reverse). The
amplified VP7 gene was sequenced as 1062 nucleotides (nt)
long and 100% homogenous with group A human rotavirus
serotype G1 VP7 gene, (GenBank Accession No. 10242241),
and performed PCR again using the same forward primer
above and the reverse primer as P3 5-TCATAGT-
TCGTCTTTTTCAGATACTCTATAATAAAACGCA-3 (re-
verse) to adding an endoplasmic reticulum sequence SEK-
DEL. The latter PCR products were cloned into the PUC-T
vector (Sangon). The resulting clone, PUC-T/VP7, was di-
gested with BamHI and SacI and subcloned into the binary
plasmid vector pBI121 (Clontech) to yield pBI-VP7.
Southern blot and RT-PCR analysis of VP7 gene
transferred in transformants
Agrobacterium tumefaciens LBA4404 containing either
the PBI-VP7 vector or the PBI121 mock vector were used to
transform potato plants (Solanum tuberosum cv. taiwan-
hong). The presence of the VP7 gene in the rooted plants
was investigated by Southern blot as described elsewhere
(Mason et al., 1992). Randomly 32P-labeled probe corre-
sponding to the VP7 ORF was generated using Klnow
polymerase from the NEBlot kit (New England Biolabs)
and was used in Southern hybridizations. To analyze VP7
mRNA in transgenic potato leaves, RT-PCR assay was
performed by using the primers above (P1 and P2) to am-
plify the VP7 gene. Total RNA from individual transfor-
mant fresh leaves were extracted by plant RNA extract kit
(Takara). The RT-PCR was performed with a TaKaRa One-
step RT-PCR kit (TaKaRa, Japan).
ELISA detection of the protein expression level of the
VP7 in transformant leaves
The presence of recombinant protein in the plants har-
boring the VP7 gene was tested by ELISA. Protein extracts
obtained by homogenization of transformants leaves in PBS
plus 0.05% Tween 20 were centrifuged at 10,000 g for 3
min and bound to 96-well microtiter plates (Hyclone) for 16
to 24 h at 4°C. Then the plates were blocked with 5%
defatted milk in PBS containing 0.05% Tween 20. Poly-
clonal antibody antirotavirus protein and horseradish perox-
idase IgG were added in subsequent steps. The plates were
developed by the addition of -phenylenediamine-H2O2 in
citrate buffer (pH5).
Western blot of VP7 expressed in transformant tubers
The expression of the VP7 protein in the transgenic
plants was analyzed by Western blot. Potato tuber extracts
were prepared by grinding 100 mg of freshly harvested
potato tuber slices in the presence of liquid nitrogen and the
resulting powder was resuspended in SDS–PAGE sample
buffer (50 mM Tris, pH 7.5, 1 mM PMSF, 8 M urea, 1%
SDS, 2 mM DTT, and 2% mercaptoethanol), boiled for 10
min, electrophoresed in 12% SDS–PAGE, and blotted to an
PVDF membrane (Roche). The membrane was blocked
overnight with PBS containing 0.05 Tween 20 (PBST), 5%
skim milk (all subsequent steps were performed using this
buffer), and incubated with a goat anti-human rotavirus
polyclone antibody (ABI129, Chemicon) for 2 h at 37°C.
The membrane was then washed in PBST and incubated
with an alkaline phosphatase labeled anti-goat Ig mouse
antiserum for 1 h at 37°C. After washing three times the
reaction was developed by the addition of the substrate
chemiluminescence (chemiluminescence detecting kit,
Roche).
Immunogenicity test in mice
Plant no. 4, which expressed high levels of VP7, was
used to produce tubers in a greenhouse and later the tubers
were used to feed mice. The VP7 protein levels in the tubers
was 4.2 g mg1 by ELISA detection. To investigate the
induction of protective immune responses to plant-derived
VP7, 40 mice were equally divided into four groups. Each
group was directly fed potato tuber slices containing 42 g
or double of VP7 on day 0,7,14, and 42, with 10 g of CT
or CT-B (Sigma) as mucosal adjuvant. Mock-transformed
potatoes plus the same adjuvant were fed to the control
group. The mice were fasted overnight and caged separately
(one mouse in one cage) before being fed potato tubers
covered with adjuvants. The potato slices were left in the
cage until all of them were consumed or left overnight,
whichever was earlier. For the duration of the immuniza-
tion, mice were fed regular animal food and separated by
groups. Before the first immunization and after the second
and the later boosters, mice were tail-bled. Antibody in the
serum against HRV-VP7 was tested by ELISA, using re-
combinant VP7 as the antigen, of serial dilutions of sera
from immunized and control mice. Differences between the
groups were evaluated by using the Student’s t-test, where
P  0.05 was considered statistically significant.
Neutralization assay
To determine neutralizing anti-HRV antibodies in sera
and stools, sera and stools obtained from mice were tested
by a microneutralization assay as described previously
(Matson et al., 1993). Briefly, sera and stools from mice
were heat-inactivated at 56°C for 30 min and incubated with
Wa strain rotavirus. A reduction in the number of HRV-
infected cells of greater than 60% with respect to the num-
ber in control wells was considered to indicate neutraliza-
tion. Neutralizing titers were expressed as the reciprocal of
the highest dilution of sera or stools yielding neutralization,
as described.
341Y.Z. Wu et al. / Virology 313 (2003) 337–342
Acknowledgments
Y.-Z. Wu and J.-T. Li contributed equally to this
study. This work was supported by National Key Basic
Research Program of China (2001CB510001) and Na-
tional Natural Science Foundation of China (NSFC
30170882). We are grateful to Prof. Yan Pei for supply-
ing PBI121 plasmids, Agrobacterium tumefaciens
LBA4404 and Taiwanhong potato plant. We also sin-
cerely thank Prof. Fang Zhao-Yin for giving human
group A rotavirus cDNA and Dr. Elschner for kindly
giving us rotavirus Wa for later neutralize assay.
References
Andrew, M.E., Boyle, D.B., Coupar, B.E., Reddy, D., Bellamy, A.R., Both,
G.W., 1992. Vaccinia-rotavirus VP7 recombinants protect mice against
rotavirus-induced diarrhoea. Vaccine 10, 185–191.
Avendano, P., Matson, D.O., Long, J., Whitney, A., Matson, C.C., Pick-
ering, L.K., 1993. Cost associated with office visits for diarrhea in
infants and toddlers. Pediatr. Infect. Dis. 12, 897–902.
Berner, R., Schumacher, R.F., Hameister, S., Forster, J., 1999. Occurrence
and impact of community acquired and nosocomial rotavirus infec-
tions: a hospital-based study over 10 years. Acta Paediatr. Suppl. 426,
48–52.
Both, G.W., Lockett, L.J., Janardhana, V., Edwards, S.J., Bellamy, A.R.,
Graham, F.L., Prevec, L., Andrew, M.E., 1993. Protective immunity to
rotavirus-induced diarrhoea is passively transferred to newborn mice
from naive dams vaccinated with a single dose of a recombinant
adenovirus expressing rotavirus VP7sc. Virology 193, 940–950.
Choi, A.H., Basu, M., Rae, M.N., McNeal, M.M., Ward, R.L., 1998.
Particle-bombardment-mediated DNA vaccination with rotavirus VP4
or VP7 induces high levels of serum rotavirus IgG but fails to protect
mice against challenge. Virology 250, 230–240.
Coste, A., Sirard, J.C., Johansen, K., Cohen, J., Kraehenbuhl, J.P., 2000.
Nasal immunization of mice with virus-like particles protects offspring
against rotavirus diarrhea. J. Virol. 74, 8966–8971.
Giammarioli, A.M., Mackow, E.R., Fiore, L., Greenberg, H.B., Ruggeri,
F.M., 1996. Production and characterization of murine IgA monoclonal
antibodies to the surface antigens of rhesus rotavirus. Virology 225,
97–110.
Glass, R.I., Kilgore, P.E., Holman, R.C., Jin, S., Smith, J.C., Woods, P.A.,
Clarke, M.J., Ho, M.S., Gentsch, J.R., 1996. The epidemiology of
rotavirus diarrhea in the United States: surveillance and estimates of
disease burden. J. Infect. Dis. 174, 5–11.
Haq, T.A., Mason, H.S., Clements, J.D., Arntzen, C.J., 1995. Oral immu-
nization with a recombinant bacterial antigen produced in transgenic
plants. Science 268, 714–719.
Herrmann, J.E., Chen, S.C., Jones, D.H., Tinsley-Bown, A., Fynan, E.F.,
Greenberg, H.B., Farrar, G.H., 1999. Immune responses and protection
obtained by oral immunization with rotavirus VP4 and VP7 DNA
vaccines encapsulated in microparticles. Virology 259, 148–153.
Hoshino, Y., Sereno, M.M., Midthun, K., Flores, J., Kapikian, A.Z.,
Chanock, R.M., 1985. Independent segregation of two antigenic spec-
ificities (VP3 and VP7) involved in neutralization of rotavirus infec-
tivity. Proc. Natl. Acad. Sci. USA 82, 8701–8704.
Johansen, K., Bennet, R., Bondesson, K., Eriksson, M., Hedlund, K.O., De
Verdier Klingenberg, K., Uhnoo, I., Svensson, L., 1999. Incidence and
estimates of disease burden of rotavirus in Sweden. Acta Paediatr.
Suppl. 426, 20–23.
Johansen, K., Svensson, L., 1997. Neutralization of rotavirus and recog-
nition of immunologically important epitopcs on vp4 and vp7 by
human IgA. Arch. Virol. 142, 1491–1498.
Klimyuk, V.I., Carroll, B.J., Thomas, C.M., Jones, J.D.G., 1993. Alkali
treatment for rapid preparation of plant material for reliable PCR
analysis. Plant J. 3, 493–494.
Mason, H.S., Lam, D.M., Arntzen, C.J., 1992. Expression of hepatitis B
surface antigen in transgenic plants. Proc. Natl. Acad. Sci. USA 89,
11745–11749.
Matson, D.O., O’Ryan, M.L., Herrera, I., Pickering, L.K., Estes, M.K.,
1993. Fecal antibody responses to symptomatic and asymptomatic
rotavirus infections. J. Infect. Dis. 167, 577–583.
Matsumura, T., Itchoda, N., Tsunemitsu, H., 2002. Production of immu-
nogenic VP6 protein of bovine group A rotavirus in transgenic potato
plants. Arch. Virol. 147, 1263–1270.
Rask, C., Fredriksson, M., Lindblad, M., Czerkinsky, C., Holmgren, J.,
2000. Mucosal and systemic antibody responses after peroral or intra-
nasal immunization: effects of conjugation to enterotoxin B subunits
and/or of co-administration with free toxin as adjuvant. APMIS 108,
178–186.
Sun, J.B., Xiao, B.G., Lindblad, M., Li, B.L., Link, H., Czerkinsky, C.,
Holmgren, J., 2000. Oral administration of cholera toxin B subunit
conjugated to myelin basic protein protects against experimental auto-
immune encephalomyelitis by inducing transforming growth factor-
beta-secreting cells and suppressing chemokine expression. Int. Immu-
nol. 12, 1449–1457.
Tacket, C.O., Mason, H.S., Losonsky, G., Clements, J.D., Levine, M.M.,
Arntzen, C.J., 1998. Immunogenicity in humans of a recombinant
bacterial antigen delivered in a transgenic potato. Nat. Med. 4, 607–
609.
Wang, L., Huang, J.A., Nagesha, H.S., Smith, S.C., Phelps, A., Holmes, I.,
Martyn, J.C., Coloe, P.J., Reeves, P.R., 1999. Bacterial expression of
the major antigenic regions of porcine rotavirus VP7 induces a neu-
tralizing immune response in mice. Vaccine 17, 2636–2645.
Yu, J., Langridge, W.H., 2001. A plant-based multicomponent vaccine
protects mice from enteric diseases. Nat. Biotechnol. 19, 548–552.
342 Y.Z. Wu et al. / Virology 313 (2003) 337–342
